SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

New order win worth Rs 187.61 crore lifts Panacea Biotec

17 Dec 2012 Evaluate

Panacea Biotec  is currently trading at Rs 122.50, up by 8.30 points or 7.27% from its previous closing of Rs 114.20 on the BSE.

The scrip opened at Rs 116.60 and has touched a high and low of Rs 125.00 and Rs 116.60 respectively. So far 15019 shares were traded on the counter.

The BSE group 'B' stock of face value Re 1 has touched a 52 week high of Rs 149.75 on 17-Sep-2012 and a 52 week low of Rs 63.50 on 04-Jun-2012.

Last one week high and low of the scrip stood at Rs 122.00 and Rs 114.00 respectively. The current market cap of the company is Rs 744.81 crore.

The promoters holding in the company stood at 74.81% while Institutions and Non-Institutions held 2.91% and 22.28% respectively.

Panacea Biotec, India’s second largest producer of vaccines and a highly progressive research based health management company has bagged Government of India’s orders for supply of 345 million doses of Trivalent Oral Polio Vaccines (tOPV) and Bivalent Oral Polio Vaccine (bOPV) worth Rs 187.61 crore.

The order is to be supplied during the period December 2012 till May 2013 to meet the requirements of National Immunisation Days (NIDs) and Supplementary National Immunisation Days (SNIDs).

As per the order, the company will supply 125 million doses of tOPV in the month of December 2012 and 70 million doses of tOPV in the month of January 2013 for the NIDs. Besides, the company will also supply a total of 150 million doses of bOPV to meet the requirements of SNIDs - 100 million doses in the month of February 2013 and 50 million doses in the month of May 2013.

Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.

Panacea Biotec Share Price

342.95 -15.05 (-4.20%)
20-Apr-2026 14:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1233.40
Cipla 1230.25
Zydus Lifesciences 937.00
Lupin 2333.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×